Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
4.11 (USD) • At close April 25, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 55.252 | 0.682 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 7.973 | 0.167 | 0.62 | 0.521 | 0.3 | 0.008 | 0 |
| Gross Profit
| 47.279 | 0.515 | -0.62 | -0.521 | -0.3 | -0.008 | 0 |
| Gross Profit Ratio
| 0.856 | 0.755 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 34.082 | 49.899 | 71.441 | 72.338 | 98.148 | 99.271 | 0.02 |
| General & Administrative Expenses
| 0 | 0 | 100.999 | 62.742 | 27.517 | 6.944 | 1.205 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 290.664 | 117.928 | 100.999 | 62.742 | 27.517 | 6.944 | 1.205 |
| Other Expenses
| 0 | 0 | -0.11 | -2.056 | -0.008 | -49.556 | -0.05 |
| Operating Expenses
| 324.746 | 167.827 | 172.44 | 135.08 | 125.665 | 106.215 | 1.225 |
| Operating Income
| -277.467 | -167.312 | -172.44 | -135.08 | -125.665 | -106.215 | -1.225 |
| Operating Income Ratio
| -5.022 | -245.326 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -56.859 | -34.28 | -25.283 | -8.803 | -3.403 | -148.916 | -0.063 |
| Income Before Tax
| -334.326 | -201.592 | -197.723 | -143.883 | -129.068 | -255.131 | -1.288 |
| Income Before Tax Ratio
| -6.051 | -295.589 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 25.283 | 4.211 | 4.25 | -45.387 | 0.013 |
| Net Income
| -334.326 | -201.592 | -223.006 | -148.094 | -133.318 | -209.744 | -1.288 |
| Net Income Ratio
| -6.051 | -295.589 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -5.29 | -3.93 | -5.7 | -4 | -4.01 | -8.48 | -0.15 |
| EPS Diluted
| -5.29 | -3.93 | -5.7 | -4 | -4.01 | -8.48 | -0.15 |
| EBITDA
| -261.522 | -159.049 | -171.82 | -134.559 | -124.187 | -250.946 | -0.05 |
| EBITDA Ratio
| -4.733 | -233.21 | 0 | 0 | 0 | 0 | 0 |